Micronoma has named Eddie Adams as chief scientific officer, company cofounder Greg Poore as chief analytic officer, and Darryl Garrison as chief operating officer.
Poore, now responsible for guiding further development of the firm's analytic and machine learning technology, is the first author of Micronoma's foundational Nature paper, a graduate of Duke University's biomedical engineering program, and currently a double-doctoral candidate in the University of California, San Diego's medical scientist training program.
Adams will lead the scientific development of Micronoma's diagnostic assays and its growing of the scientific team, with immediate responsibility for leading a utility trial for Micronoma's first offering, a diagnostic for the early detection of lung cancer. He holds a PhD from MIT and his background spans chemistry, immunology, nanotechnology, and molecular biology. He has developed diagnostics programs for the early detection of bloodstream infection and has extensive experience in sample preparation including commercializing methods and kits to extract nucleic acids for microbiome analyses.
Garrison holds more than 20 years of experience in the molecular diagnostic industry, having set up and run diagnostics laboratories at many of the major clinical cancer firms in Southern California. For Micronoma, he will establish the firm's CLIA labs, as well as assist with all processes and workflow implementation to ensure that the company is ready to process patient samples.